OSI-DFCI Grant Announcement

FOR IMMEDIATE RELEASE
February 27, 2020

The Osteosarcoma Institute to Fund Clinical Trial in Recurrent Osteosarcoma at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and University of California San Francisco

The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.

Dallas, TX — February 27, 2020 — The Osteosarcoma Institute (OSI) is pleased to announce funding support for a clinical trial of a novel, precision oncology approach to the recalcitrant problem of recurrent osteosarcoma. Osteosarcoma is the most common bone tumor among children, adolescents, and young adults and, unlike many other pediatric cancers, there has been no significant improvement in outcomes in the past 30 years. Effective new treatments are desperately needed for patients whose disease recurs after initial therapy.

The OSI clinical trial grant is to the Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, for a Phase II single arm study of olaparib (an FDA-approved PARP inhibitor) and ceralacertib/AZD6738 (an investigational ATR kinase inhibitor) in patients with recurrent osteosarcoma. Both study drugs are orally-administered and are products of AstraZeneca which is supporting the trial by providing these agents. The trial also features important correlative biology studies to help understand what genomic characteristics and biomarkers can best predict patients who may respond to this regimen. The trial will be led by Katherine A. Janeway, MD MMSc, Senior Physician at Dana-Farber/Boston Children’s and Director of Clinical Genomics at DFCI. Alejandro Sweet-Cordero, MD, Benoiff UCSF Professor in Children’s Health and Director of the Molecular Oncology Initiative, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, is co-leader of the project and will direct the correlative biology work. The trial is expected to open at both DFCI and UCSF this summer and at least one other institution in late 2020.

Study leader Katherine Janeway, MD, commented “we are excited to be partnering with OSI and AstraZeneca to launch a trial of this drug combination in osteosarcoma. In this phase 2 trial of olaparib and ceralacertib, OSI is supporting a unique linkage between Dr. Sweet-Cordero’s basic science laboratory and our clinical trials group ensuring that we use every opportunity to advance our understanding of osteosarcoma.”

OSI Director Lee Helman, MD, noted, “The OSI clinical trial review committee selected this study to further the OSI’s mission to dramatically improve the life expectancy of relapsed and metastatic osteosarcoma patients. Together with our previously-announced support of another clinical trial and a pre-clinical biology study, OSI aims to provide immediate hope for current patients and long-term hope for better, less toxic treatments for future patients. We will be discussing these projects at the MIB Agents FACTOR Conference on Saturday, February 29, 2020.

About the Osteosarcoma Institute

The Osteosarcoma Institute (www.osinst.org, @OSInstitute), is a 501(c)(3) public charity formed in 2017 to dramatically improve treatments for osteosarcoma patients, particularly those with relapsed and metastatic disease.  It funds pre-clinical research to gain understanding of the biology of osteosarcoma, and clinical trials to evaluate the safety and effectiveness of potential new treatments.

Media Contact
Osteosarcoma Institute:
info@osinst.org
source:  The Osteosarcoma Institute

###

Click here for a version of this press release.

Donate